Preview Mode Links will not work in preview mode

Jul 16, 2020

Proceedings from the first in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Virginia Kaklamani, Ms Marissa Marti, Dr Joyce O’Shaughnessy and Mr Daniel G Pizana.

  • Introduction (00:00)
  • Neoadjuvant therapy for patients with localized HER2-positive breast cancer (2:20)
  • Activity and tolerability of T-DM1 as adjuvant therapy (7:24)
  • Clinical experience with neratinib as postadjuvant therapy for patients with HER2-positive breast cancer (11:00)
  • Results of the KATHERINE study comparing T-DM1 to trastuzumab and the APHINITY trial evaluating pertuzumab, trastuzumab and chemotherapy as adjuvant therapy for HER2-positive early breast cancer (15:48)
  • Benefits and risks with the novel agents trastuzumab deruxtecan and tucatinib for HER2-positive metastatic breast cancer (mBC) (26:13)
  • Role of the immune checkpoint inhibitors atezolizumab and pembrolizumab and the novel antibody-drug conjugate sacituzumab govitecan for triple-negative breast cancer (38:49)
  • Genomic testing for patients with breast cancer; integration of PARP inhibitors into the therapeutic algorithm for patients with mBC and germline BRCA mutations (52:59)
  • Efficacy and tolerability of the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib for ER-positive, HER2-negative mBC (1:07:56)
  • Activity of alpelisib in patients with ER-positive mBC and PIK3CA mutations; results of the SOLAR-1 trial evaluating alpelisib with fulvestrant (1:16:19)

CNE information and select publications